Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GREEN MEMORY: GV-971 in Mild to Moderate Alzheimer's Disease
NCT04520412Phase 3Suspended
- Sponsor
- Green Valley
- Start
- Oct 2020
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 3 trial of sodium oligomannate in Alzheimer's disease (AD), sponsored by Green Valley. Started Oct 2020; status: suspended.
02
Drugs
sodium oligomannate
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04520412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04520412.